These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 18430393)

  • 1. Over-suppression of bone turnover: does it exist?
    Compston J
    Curr Osteoporos Rep; 2007 Dec; 5(4):179-85. PubMed ID: 18430393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skeletal accumulation of bisphosphonates: implications for osteoporosis treatment.
    Allen MR
    Expert Opin Drug Metab Toxicol; 2008 Nov; 4(11):1371-8. PubMed ID: 18950279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of antiresorptive therapy on the structural and material properties of bone strength].
    Kishimoto H
    Clin Calcium; 2016 Jan; 26(1):107-15. PubMed ID: 26728537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Management of osteoporosis by using biochemical markers for bone turnover].
    Mizunuma H
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():227-30. PubMed ID: 18159710
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacological topics of bone metabolism: recent advances in pharmacological management of osteoporosis.
    Suzuki A; Sekiguchi S; Asano S; Itoh M
    J Pharmacol Sci; 2008 Apr; 106(4):530-5. PubMed ID: 18431035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New bone density conservation agents for osteoporosis under research and development: ED-71].
    Hagino H
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():454-8. PubMed ID: 18161148
    [No Abstract]   [Full Text] [Related]  

  • 7. Anabolic therapies for osteoporosis.
    Uihlein AV; Leder BZ
    Endocrinol Metab Clin North Am; 2012 Sep; 41(3):507-25. PubMed ID: 22877427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New bone density conservation agents for osteoporosis under research and development: Strontium ranelate].
    Shiraki M
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():447-53. PubMed ID: 18161147
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacological topics of bone metabolism. Preface.
    Togari A; Ohya K
    J Pharmacol Sci; 2008 Apr; 106(4):529. PubMed ID: 18431034
    [No Abstract]   [Full Text] [Related]  

  • 10. [Mechanisms of action of anticatabolic drugs used in osteoporosis therapy].
    Kryśkiewicz E; Lorenc RS
    Endokrynol Pol; 2009; 60(2):134-44. PubMed ID: 19396757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination anabolic and antiresorptive therapy for osteoporosis.
    Cusano NE; Bilezikian JP
    Endocrinol Metab Clin North Am; 2012 Sep; 41(3):643-54. PubMed ID: 22877434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biochemical markers of bone turnover. New aspect. Biochemical markers of bone turnover in long term treatment with bisphosphonate].
    Asano S; Suzuki A; Itoh M
    Clin Calcium; 2009 Aug; 19(8):1179-85. PubMed ID: 19638702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One year in review 2018: progress in osteoporosis treatment.
    Figliomeni A; Signorini V; Mazzantini M
    Clin Exp Rheumatol; 2018; 36(6):948-958. PubMed ID: 30526765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting WNT signaling in the treatment of osteoporosis.
    Baron R; Gori F
    Curr Opin Pharmacol; 2018 Jun; 40():134-141. PubMed ID: 29753194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New bone density conservation agents for osteoporosis under research and development: Zoledronate].
    Wada S; Fukawa T; Kamiya S
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():421-5. PubMed ID: 18161143
    [No Abstract]   [Full Text] [Related]  

  • 16. [Outline of Guidelines 2004 for bone marker in osteoporosis].
    Nishizawa Y
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():37-41. PubMed ID: 18161079
    [No Abstract]   [Full Text] [Related]  

  • 17. Bi-directionally selective bone targeting delivery for anabolic and antiresorptive drugs: a novel combined therapy for osteoporosis?
    Liu J; Zhang H; Dong Y; Jin Y; Hu X; Cai K; Ma J; Wu G
    Med Hypotheses; 2014 Dec; 83(6):694-6. PubMed ID: 25459136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological agents and natural compounds: available treatments for osteoporosis.
    Martiniakova M; Babikova M; Omelka R
    J Physiol Pharmacol; 2020 Jun; 71(3):. PubMed ID: 32991310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Morphological analysis of bone dynamics and metabolic bone disease. Does bisphosphonate treatment cause severely suppressed bone turnover (SSBT) ?].
    Kondo N; Yoda T
    Clin Calcium; 2011 Apr; 21(4):583-7. PubMed ID: 21447926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medication-related osteonecrosis of the jaw in osteoporotic patients: prevention and management.
    Chan BH; Yee R; Puvanendran R; Ang SB
    Singapore Med J; 2018 Feb; 59(2):70-75. PubMed ID: 29568850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.